The UK antibody developer Crescendo Biologics Ltd has appointed Philip Bland-Ward as its chief scientific officer to advance the company’s immuno-oncology and drug conjugate programmes to clinical proof-of-concept.
Dr Bland-Ward joins from Kymab Ltd where he was responsible for managing that company’s lead antibody programme. He has also had senior positions at Cambridge Antibody Technology, now part of AstraZeneca Plc, and PanGenetics BV. He holds a BPharm degree in pharmacy and a PhD in pharmacology, both from King’s College London.
Crescendo Biologics announced the appointment on 4 April 2017.
Copyright 2017 Evernow Publishing